Name: Kevin Thornal
New title: Group president for global businesses and the Americas, Zimmer Biomet
Previous title: President and CEO, Nevro
Zimmer Biomet named Kevin Thornal to the newly created position of group president for global businesses and the Americas, effective July 1, the orthopedics device maker said Tuesday.
Thornal was president and CEO of spinal cord stimulation company Nevro from April 2023 until it was acquired by Globus Medical last month for about $250 million. Before that, he was group president of global diagnostic solutions at Hologic, where he held a series of leadership positions beginning in 2014.
Before joining Hologic, Thornal worked in sales, marketing and business development at Stryker for 10 years, including as head of North American sales for its interventional spine business.
In his new role, Thornal will oversee the Americas commercial organization and lead business strategy and execution for the global knees, hips, S.E.T. and data, technology and enabling solutions units.
Thornal will receive an annual base salary of $850,000, with a bonus opportunity in 2025 equal to 100% of his salary on a prorated basis, if performance goals are achieved, Zimmer said in a securities filing. He will also receive restricted stock units valued at $2.65 million and performance-based restricted stock units valued at $2.65 million.
In connection with Thornal’s appointment, Mark Bezjak will remain president of the Americas but will no longer be an executive officer, according to the filing. Bezjak was promoted to president of the Americas from president of North America in September 2023, shortly after CEO Ivan Tornos became Zimmer’s top executive.
